To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Launched by ASTRAZENECA · Jul 18, 2011
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male of female aged 20 years or more
- • History of reflux esophagitis
- • Ongoing (until date of Visit 1) treatment with rabeprazole 10 mg, given once daily, for at least 4 weeks.The subject must take rabeprazole at least 4 days a week in the past 7 days prior to Visit 1.
- • Persisting symptoms of heartburn experienced at least 2 days during the past 7 days prior to Visit 1.
- Exclusion Criteria:
- • Use of other PPIs and/or H2RA during rabeprazole treatment
- • History or having other gastrointestinal diseases
- • History of upper gastrointestinal surgery
- • Initiation of medications that can affect digestive functions within 4 weeks before study treatment
- • Inability to complete questionnaires
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Masataka Date
Study Director
AZ K.K.
Makiko Abe
Study Chair
AZ K.K
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials